We are pleased to announce the Synagis® (palivizumab) distribution program for the 2011-2012 respiratory syncytial virus (RSV) season, which is November through April in the United States. RSV is the most common cause of bronchiolitis and pneumonia among children younger than 1.
During the RSV season, we will approve the monthly administration of Synagis® (palivizumab) for at-risk children younger than two. Synagis® (palivizumab) is a humanized monoclonal antibody that provides passive immunity against RSV. It is intended to decrease the morbidity and mortality associated with RSV lower respiratory tract disease in at-risk children.
For more information, read the complete article in the September edition of Partners in Health UpdateSM.